ChromaDex (NASDAQ:CDXC) Raised to “Strong-Buy” at StockNews.com

ChromaDex (NASDAQ:CDXC) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Monday.

A number of other equities research analysts also recently weighed in on the company. Roth Mkm raised their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright increased their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th.

ChromaDex Stock Performance

Shares of NASDAQ:CDXC traded up $0.08 during midday trading on Monday, hitting $5.50. 475,142 shares of the stock were exchanged, compared to its average volume of 360,081. The company has a market capitalization of $420.11 million, a PE ratio of 550.55 and a beta of 2.21. ChromaDex has a 52-week low of $1.51 and a 52-week high of $7.97. The business’s fifty day simple moving average is $5.62 and its two-hundred day simple moving average is $5.00.

Insiders Place Their Bets

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares in the company, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 9.64% of the company’s stock.

Hedge Funds Weigh In On ChromaDex

A number of institutional investors have recently modified their holdings of the company. BSW Wealth Partners acquired a new position in ChromaDex in the 3rd quarter valued at $324,000. Barclays PLC boosted its holdings in ChromaDex by 322.1% during the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after acquiring an additional 53,472 shares during the period. Sargent Investment Group LLC acquired a new stake in shares of ChromaDex in the fourth quarter valued at about $263,000. FMR LLC bought a new position in shares of ChromaDex in the third quarter worth about $55,000. Finally, JPMorgan Chase & Co. increased its stake in shares of ChromaDex by 11.1% in the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after purchasing an additional 33,150 shares during the period. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.